On Sept. 24 it announced plans to begin human trials. Its stock was up close to 2 percent at closing. GlaxoSmithKline’s stock rose on the news as well. The pharmaceutical giant came to its Ebola research through the acquisition of a small …
We maintain our Sell rating on GlaxoSmithKline Pharma (GSK) and revise our TP to Rs1,525 (earlier Rs1,390) based on 24x March’19E EPS of Rs63.4. GSK’s Q2FY18 results exceeded our and consensus estimates. GSK revenue grew by …
But the biggest dividend among Big Pharma stocks belongs to GlaxoSmithKline PLC (NYSE:GSK). The Brentford, England-based company’s 5% dividend yield stands well above other health care giants such asJohnson & Johnson …
One stock that might be an intriguing choice for investors right now is GlaxoSmithKline plc GSK. This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision activity, and is in great …
For 2018, EPS guidance was given, as last year, bearing in mind the uncertainty over the timing and impact of possible generic competition to GSK's Advair asthma drug in the US. In the event of no substitutable generic competitor, …
The stock fell a further 1.5 percent on Thursday. 01/19 GLAXOSMITHKLINE: Findings from GlaxoSmithKline plc Provides New Data about Comb.. 01/19 GLAXOSMITHKLINE: Recent Findings from GlaxoSmithKline plc Has …
This is a bit of a knee-jerk response. Arguably, at these sort of ratings the stock is already discounting a worst-case scenario.'' GSK currently trades at less than 13 times the consensus forecast for 2003 earnings -- a discount of around …
CNN14y
Century Aluminum (NASDAQ:CENX): JP Morgan moves the stock to Underweight from Neutral. GlaxoSmithKline (NYSE:GSK): Pharmaceutical giant GlaxoSmithKline sees its stock downgraded to Hold from Buy at Deutsche …